Document is current
Any future updates will be listed below
-
Authors
Long, Alan W
Xu, Hong
Santich, Brian H
Guo, Hongfen
Hoseini, Sayed Shahabuddin
de Stanchina, Elisa
Cheung, Nai-Kong V
-
Funding
Funding for this research was provided by:
NCI Cancer Center Support Grant (P30 CA008748)
- License Information
-
More Information
Article History
Received: 4 November 2023
Accepted: 22 March 2024
First Online: 23 April 2024
Declarations
:
: Both MSKCC and N.-K.V.C. have financial interests in Y-mAbs and Abpro. N.-K.V.C. reports receiving past commercial research grants from Y-mAbs Therapeutics Inc. and Abpro Inc. N.-K.V.C. is a scientific advisory board member of Eureka Therapeutics. N.-K.V.C. is the inventor of issued patents licensed by MSK to Biotec Pharmacon. N.-K.V.C. has reported owning stock options in Eureka Therapeutics Inc. N.-K.V.C. is as an inventor on approved and pending patents filed by MSK. The remaining authors declare no competing financial interests. S.S.H. was named as co-inventor in several patents on bispecific antibodies filed by Memorial Sloan Kettering Cancer Center and Ymabs Therapeutics.
